No Data
No Data
Express News | Coeptis Therapeutics Closes on $4.3 Million of Series a Preferred Offering
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
Bolsters Company's Corporate MissionFinancing Led by Board Member and Priced at Premium to Market PriceWEXFORD, Pa., June 20, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (t
Ladenburg Thalmann Downgrades Coeptis Therapeutics(COEP.US) to Hold Rating
Ladenburg Thalmann analyst Aydin Huseynov downgrades $Coeptis Therapeutics(COEP.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 30.1% and a total average return of
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
WEXFORD, Pa., May 30, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersMustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASD
10-Q: Quarterly report
No Data